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Disease Burden Estimates for
Infectious Diseases
Baseline comprehensive estimates of
infectious disease (ID) burden are needed
for effective planning and prioritizing of
limited public health resources. Over the
last three decades, efforts have been made
to derive and apply methods to estimate
disease burden at population scales. In
particular, the Global Burden of Disease
(GBD) project [1] has made important
progress in this area methodologically and
in terms of output estimates, and is based
on available evidence that therefore sup-
ports health-care policy making [2]. While
the incidence of IDs has in general
decreased substantially in Europe over
the last century, newly emerging and re-
emerging IDs pose serious threats to
population health [3,4]. According to
recent estimates from the GBD project,
IDs represent less than 10% of the total
burden of disease in Europe [5,6]. This
figure, however, might underestimate the
real burden due to IDs in the European
region because it does not fully take into
account the whole spectrum of long-term
sequelae caused by infections. Here, we
outline an approach taken to adapt
burden estimate methods to the European
situation; the approach capitalizes on the
generally good data quality in the Euro-
pean Union, but also takes formal, quan-
titative account of underreporting and
under-ascertainment, as well as the burden
of all important sequelae associated with
an infection.
In the autumn of 2006, the Dutch
National Institute for Public Health and
the Environment (RIVM) conducted a
pilot study on behalf of the European
Centre for Disease Prevention and Con-
trol (ECDC) to illustrate the potential of
the disease burden concept [2], to explore
data availability and quality, and to
stimulate debate [7–9]. In July 2009, the
Burden of Communicable Diseases in
Europe (BCoDE) project was launched
by the ECDC with the major objectives of
furthering development of the methodolo-
gy to estimate the burden of IDs, and
providing estimates of the current and
future burden of IDs in the EU member
states and European Economic Area/
European Free Trade Association coun-
tries. These estimates take into account the
burden of acute illness and of fatal cases,
as well as of sequelae and complications
associated with the infectious agent (e.g.,
infection-associated cancers). To do this in
a consistent way, an approach was devel-
oped that attributes all burden generated
by an infection with a specific pathogen to
the infection event using information on
disease progression. Future aims of the
project are to consider the dynamic
aspects of ID epidemics, the impact of
public health interventions, and emerging
trends like demographic change and
climate change.
Composite Health Measures for
Infectious Diseases
Composite measures for disease burden
were used on a global scale by the World
Bank [10] and later in landmark studies of
the GBD project [1,5,11]. Those studies
estimated the global burden of a whole
spectrum of diseases, including conditions
as diverse as mental illness, injuries,
The Policy Forum allows health policy makers
around the world to discuss challenges and
opportunities for improving health care in their
societies.
Citation: Kretzschmar M, Mangen M-JJ, Pinheiro P, Jahn B, Fe `vre EM, et al. (2012) New Methodology for
Estimating the Burden of Infectious Diseases in Europe. PLoS Med 9(4): e1001205. doi:10.1371/
journal.pmed.1001205
Published April 17, 2012
Copyright:  2012 Kretzschmar et al. This is an open-access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are credited.
Funding: The study was funded by the European Centre for Disease Prevention and Control (Specific
agreement No 1 to Framework Partnership Agreement GRANT/2008/003). The funders are also participating in
the research project and are co-authors of the paper.
Competing Interests: MJM received funding for a related tender by ECDC. AH and EF are members of the
World Health Organization’s Foodborne Disease Burden Epidemiology Reference Group (FERG). AC and PK are
employed by the European Centre for Disease Prevention and Control (ECDC, http://www.ecdc.europa.eu) and
ECDC provided a grant which co-funded this study.
Abbreviations: BCoDE, Burden of Communicable Diseases in Europe; DALY, disability-adjusted life year;
ECDC, European Centre for Disease Prevention and Control; GBD, Global Burden of Disease; ID, infectious
disease.
* E-mail: mirjam.kretzschmar@rivm.nl
Provenance: Not commissioned; externally peer reviewed.
PLoS Medicine | www.plosmedicine.org 1 April 2012 | Volume 9 | Issue 4 | e1001205chronic diseases, and IDs. To comprehen-
sively present and compare the impact of
these conditions on population health and
mortality, composite measures of popula-
tion health were developed and used to
sum up the impact of adverse health
events on quality of life and life expectancy
in one single metric [2,12]. The impact of
every adverse event on health can be
measured by the number of life years lost
due to premature death and the number of
life years lost due to disability. The latter
requires measuring the impact of disease
on quality of life using disability weights.
Both the number of life years lost due to
premature death and the number of life
years lost due to disability are estimated by
use of a reference that reflects an ideal
health goal, and add up to a disability-
adjusted life year (DALY) [2].
There are a number of challenges when
computing the disease burden for ID. One
difficulty is the fact that symptomatic as
well as asymptomaticinfections maylead to
long-term chronic sequelae, which might
therefore not always be recognized as being
originally caused by an infection [13].
More generally, for many IDs the possible
relationshipswithlaterchronicsequelaeare
not clearly established, and therefore crite-
ria have to be specified to decide when the
strength of evidence is sufficient for attri-
buting long-term morbidity and/or mor-
tality associated with those sequelae to their
infectious cause [14].
Another difficulty in estimating the
burden of ID is the fact that they occur
on very different time scales. While for an
influenza infection acute illness and sequel-
ae occur within a time period of weeks, for
HIV infection and hepatitis B infection the
time between acute infection and death
may span decades. Attributing long-term
sequelae to infection with a specific path-
ogen therefore may require adding disease
burden that occurs over long time periods.
This is visualized by plotting individual life
trajectories in a Lexis diagram, a tool used
by demographers to represent demograph-
ic processes in the time–age plane [15,16].
The Lexis diagram shows how the inci-
dence of infection and the resulting sequel-
ae may be distributed inthe time–age plane
(Figure 1A). For an infection with only
short-term symptoms and sequelae, inci-
denceand sequelaeliewithina well-defined
time slice in the plane, whereas for
infections with long-term sequelae or late
onset of sequelae, these are distributed over
a larger area outside the time slice under
consideration (Figure 1B and 1C). In a
steady state situation this is not a problem,
but if there are temporal fluctuations in
incidence, interpretation and comparison
of disease burdens is more intricate.
Pathogen-Based Incidence
Approach
In the first phase of the BCoDE project,
the disease burden was estimated for four
countries (Estonia, Germany, Italy, and
The Netherlands) and 32 IDs (Table 1).
The diseases included in the BCoDE study
were selected from a list of 49 IDs that fall
under the mandate of the ECDC as part of
the network for epidemiological surveil-
lance and control of communicable dis-
eases in the European Union and Euro-
pean Economic Area/European Free
Trade Association states [17]. For the
selection, a list of criteria was applied that
assessed the importance of an ID and the
potential difficulties in estimating the
burden (e.g., the availability of disability
weights) [18]. While some nosocomial
pathogens are on the list for future burden
estimates, their estimation was postponed
to a later stage of the project because they
require methods to deal with co-morbidity
and are less amenable to the pathogen-
based approach.
The aim of the pilot study was to gain
experience with the new methodological
approach and to assess data availability
and quality. We obtained notification data
and other surveillance data from national
public health institutes, performed litera-
ture reviews to extract information about
disease progression and underreporting,
and developed outcome trees for all IDs
included in the study [18]. Computational
models were developed for estimating the
burden in a standardized manner. The
disease burden was calculated as DALYs
stratified by age and sex. We used GBD
disability weights where available, and
weights from other published studies
otherwise [19]. We will update those
weights when new GBD disability weights
become available [20]. We calculated
DALYs using a pathogen-based incidence
approach, which links sequelae to their
infectious cause [7]. In this approach, the
incidence of infections from a specific
pathogen in a particular year is linked to
all related health outcomes through an
outcome tree or disease progression model
(Figure 2). An outcome tree gives a
qualitative representation of the progres-
sion of disease in time by ordering all
relevant health outcomes following infec-
tion and illustrating their conditional
dependency. To derive quantitative esti-
mates using an outcome tree, information
on the probability of entering and the time
spent in each health state was required.
This information was extracted from
published literature and validated by
expert consultation. Then, using the
incidence of an infection in a given year
as a starting point, and based on knowl-
edge of the expected frequency of health
outcomes following from the infection, the
burden of an ID was estimated.
The BCoDE project relies heavily on
notification data and on other readily
available data from surveillance systems,
which are relatively well developed in the
European context. We based our estimates
mainly on three types of data obtained
from different surveillance sources: inci-
dence of symptomatic infections (e.g.,
notification data or data from lab surveil-
lance), incidence of hospitalized cases of
infection (hospitalization data), and inci-
dence of death due to the infection (cause
of death data from vital registration
systems).
Data from routine surveillance sources
need to be adjusted to correct for under-
reporting and under-ascertainment when
estimating disease burden from those data.
Under-ascertainment refers to cases or
exposures in the community in individuals
who never seek health care and are
therefore not registered in any notification
or surveillance system. Underreporting
refers more specifically to cases in individ-
Summary Points
N The major objectives of the Burden of Communicable Diseases in Europe
(BCoDE) study are to further develop the methodology to estimate the burden
of infectious diseases (IDs), and to estimate and report on the current and
future burden of IDs in the European Union member states and European
Economic Area/European Free Trade Association countries.
N The BCoDE project uses a pathogen-based incidence approach to generate
estimates, fully taking into account all chronic and long-term sequelae that can
be causally related to an infectious agent.
N An important focus is the assessment of underreporting and under-
ascertainment in various types of incidence data.
N Future challenges are the integration of demographic changes and infection
dynamics into the methodology for estimating the burden of IDs.
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infection status is misdiagnosed or mis-
classified, and whose infection details are
therefore not passed on to national
surveillance systems.
Multiplication factors were applied to
the reported numbers of cases of a
particular disease in order to estimate the
true numbers of cases. A systematic
method for estimating these was devel-
oped, which will be fully reported else-
where. Briefly, multiplication factors were
developed by comparing incidence or
exposure in the general population (pref-
erentially determined by community-
based or serological studies) with notified
case data (including incidence of hospital-
izations, laboratory-confirmed cases, gen-
eral practitioner cases, and deaths attrib-
utable to the disease). Multiplication
factors are disease-specific since the
amount of under-reporting varies by
disease. Ideally, they should also be
country-specific (owing to variations in
disease exposure, health-care systems, and
availability of treatment, as well as cultur-
al, social, and technological differences)
and age- and sex-specific. In some infec-
tions, like influenza, even seasonal strains
will cause a varying degree of symptomatic
disease and associated health-seeking be-
havior [21]. However, we did not have
such detailed information available; in
most cases, we had only rough estimates
for the ratio of reported to unreported
cases.
Based on health outcomes defined in
outcome trees of IDs, we collected inci-
dence data for acute illness and other
health outcomes, if available. For each
health outcome, incidence data (morbidity
and mortality) were collected for a three-
year period (1 January 2005–31 December
2007) and used as input into estimation
models. These years were chosen because
the ECDC had established standards for
case reporting on the European level, and
data collection was completed at the time
the project started. For computing the
estimates, data on incidence of acute
illness were preferentially used, while data
on incidence of other health outcomes
were used for validation. If the incidence
of acute infections was not available,
incidence of morbidity or mortality was
used. Based on the three study years, a
crude annual mean incidence was estimat-
ed, stratified by age (in five-year classes)
and sex. Where necessary, these incidenc-
es were adjusted by factors correcting for
underreporting and under-ascertainment.
For sequelae, but also for other health
outcomes where no incidence data were
available, we estimated the number of
cases using the probability of the occur-
rence of outcomes, taking into consider-
ation the conditional dependency of the
different health outcomes as defined by the
outcome tree. Preliminary results are
Figure 1. The Lexis diagram shows events by age and time. (A) This Lexis diagram shows the occurrence of infection, disease, and death in
individual life histories in the time–age plane. An epidemic outbreak affects several cohorts of individuals at a specific time, but may cause disease
burden at different times later on. An age-specific intervention starts at a certain time and affects all cohorts reaching the specific age from that time
onward. It does not prevent disease burden from earlier infections. Incidence may cause burden within a time window of observation, but also at
later times within the life histories of the affected individuals. (B) Here the Lexis diagram shows the occurrence of influenza cases within the time
period of one year. All burden generated by morbidity (red) occurs also within that time period. Burden due to mortality is from deaths occurring in
the same year as infection. (C) The Lexis diagram for hepatitis B shows that the burden due to morbidity is spread out over many years following the
incident infections in the year starting at time t.
doi:10.1371/journal.pmed.1001205.g001
Table 1. Infectious diseases for which burden estimates were derived in the BCoDE
project.
Disease Group Infectious Disease
Respiratory infections Seasonal influenza
Legionellosis
Tuberculosis
Sexually transmitted infections Chlamydia
Gonococcal infections
Hepatitis B
Hepatitis C
HIV
Syphilis
Food- and waterborne infections Campylobacteriosis
Cryptosporidiosis
Infection with STEC/VTEC
Giardiasis
Hepatitis A
Listeriosis
Salmonellosis
Shigellosis
Toxoplasmosis
Creutzfeldt-Jakob disease
Zoonotic and vectorborne infections Q fever
Tick-borne encephalitis
Vaccine-preventable infections Diphtheria
Invasive haemophilus influenzae disease
Invasive pneumococcal infections
Measles
Invasive meningococcal disease
Mumps
Pertussis
Poliomyelitis
Rabies
Rubella
Tetanus
STEC/VTEC, shigatoxin-producing E. coli/verocytotoxin-producing E. coli.
doi:10.1371/journal.pmed.1001205.t001
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results will be published elsewhere.
Future Challenges and
Conclusions
The dynamics of ID transmission occurs
in widely differing time scales depending on
thepathogen.Clearly,infectionsthatspread
on the time scale of the average generation
time of a population will be closely linked to
changes in demography, social and behav-
ioral changes, and the implementation of
preventive measures. ID can influence a
population’s demography by affecting mor-
tality and therefore average life expectancy,
orbyinfluencingfertilityrates.Onthe other
hand, demography also influences the
transmission of ID by determining the
relative sizes of susceptible and vulnerable
populations. [24]. While a severe impact of
ID on the demography of entire nations has
been observed in developing countries, in
the industrialized world the aging of
populations may have an impact on the
burden ofID[25–27].Prevention programs
such as mass vaccination tend to increase
the average age at which an exposure to
infection takes place and therefore increase
the probability of severe complications for
some diseases. For some IDs, reactivation of
latent infections acquired at a young age
may occur at an older age because of
changes in the functioning of the immune
system. Finally, demographic flow leads to
shifts in the immune status of entire
populations, possibly resulting in increasing
risks of large outbreaks in vulnerable
population groups.
At present the methods used in burden
of disease calculations rest on steady state
assumptions regarding demography and
epidemiology. However, there are few IDs
for which the epidemiological situation has
remained even remotely stable over the
time span of the last 50 years, not only
because of the implementation of large-
scale prevention programs, but also be-
cause of enormous changes in mobility
patterns and life styles [28]. Also, popula-
tion densities have increased, and migra-
tion is increasingly important in determin-
ing a country’s epidemiological situation.
In addition, it is expected that climate
change will have a major impact on the
distribution of IDs within the coming
century [29]. In Europe, awareness is
increasing that pathogens that have been
limited to more tropical climates may
cause major outbreaks or even become
endemic in countries of the temperate
climate zone. Also, changes in agricultural
production systems, urbanization, and
changing contact patterns with animals
lead to increasing risks of zoonotic infec-
tions or emerging infections of zoonotic
origin. These diseases may not contribute
much to the overall burden at present, but
we would like to anticipate the future
burden that Europe might be facing if
these diseases continue to emerge on a
larger scale [30].
We used a pathogen-based incidence
approach that attributes all burden gener-
ated by an infection to the time of
incidence of the infection. While this has
the advantage of consistently attributing
the burden to its infectious cause, the
approach also has some serious limita-
tions. For many pathogens that cause
broad, nonspecific disease syndromes, it
is difficult to attribute morbidity to a
specific pathogen. Conditions like diar-
rhea, pneumonia, or encephalitis may be
caused by many different pathogens, and
usually we do not have the specific
information to attribute morbidity to
specific pathogens. Even if such informa-
tion is available, a (large) proportion of
cases may not be attributable to any
specific pathogen. Also, co-morbidity and
co-infections may play an important role,
especially in hospital settings. One strategy
to deal with these limitations may be to use
information on the occurrence of syn-
dromes as a validation tool for estimates
derived from the pathogen-based ap-
proach. These limitations highlight the
need for further research in this area.
Figure 2. An outcome tree linking exposure, infection and all sequelae. The outcome tree displays how individuals may progress through
various stages of infection, disease, and death. The process can be quantified by attaching proportions to the arrows depicting transitions, and
durations to the various health outcomes. ‘‘R’’ denotes full recovery from infection and/or disease.
doi:10.1371/journal.pmed.1001205.g002
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statistical methods for studying IDs will
provide new tools for future disease
burden estimation. Dynamic transmission
models—already widely used for the
analysis of epidemiological data and the
effects of intervention—will be used to
describe temporal dynamics of outbreaks
and the impact of large-scale intervention
measures [31]. These models will be
combined with models from mathematical
demography [16] to account for changes
in population age structure and life
expectancy. Bayesian statistical methods
for parameter estimation provide tools for
combining data from various sources into
a consistent estimate, allowing the weight-
ing of evidence according to its perceived
reliability [32]. Combining dynamic trans-
mission models that include demographic
modeling with Bayesian estimation meth-
ods will be the methodological toolkit for
future burden estimates for ID within the
BCoDE project. A toolkit for the applica-
tion of burden estimation models, which is
currently being developed by the consor-
tium, will soon be available for public
health policy makers, to support national
disease burden studies of IDs.
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